We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Could Detect Pre-Eclampsia Before Symptoms Appear

By LabMedica International staff writers
Posted on 12 Mar 2026

Pre-eclampsia is a dangerous pregnancy complication characterized by sudden high blood pressure that can threaten the lives of both mother and baby. More...

Affecting about five percent of pregnancies worldwide, the condition often develops without warning and is frequently detected only after symptoms become severe. Researchers have now identified previously hidden molecular signals that may allow clinicians to detect pre-eclampsia weeks before symptoms appear.

New research from the Milner Centre for Evolution at the University of Bath (Bath, UK) focused on gene regulation during placental development and identified molecular markers linked to early-onset pre-eclampsia. The team analyzed how genes are activated in the developing placenta and discovered that small regulatory regions derived from ancient retroviral DNA sequences play a key role in controlling placental gene activity. These viral remnants, inherited through human evolution, act as regulatory switches that influence gene expression.

The study found that two retroviral fragments—LTR8B and MER65—control the regulation of the pregnancy-specific protein PSG9, which is important for normal placental development. When this regulatory system malfunctions, placental development becomes impaired, a hallmark of early-onset pre-eclampsia. The researchers also discovered that disruptions in this system leave detectable molecular signals in maternal blood early in pregnancy, suggesting the possibility of a non-invasive diagnostic test.

These findings, published in Genome Biology, provide new insight into the biological mechanisms underlying pre-eclampsia and could lead to earlier screening methods that identify high-risk pregnancies before symptoms develop. Early detection would allow clinicians to monitor patients more closely and intervene sooner to reduce complications. The research may also support the development of future treatments targeting the regulatory pathways involved in placental gene control.

“This work shows that an ancient viral sequence can act like a manual for a placental gene,” said Dr. Manvendra Singh, lead author of the study. “By mapping the regulatory region and testing it functionally, we have now connected genome evolution to a concrete disease mechanism – and to the possibility of earlier detection.”

Related Links:
University of Bath


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.